ES2194841T3 - Procedimiento de produccion de vacunas bacterianas gram negativas. - Google Patents

Procedimiento de produccion de vacunas bacterianas gram negativas.

Info

Publication number
ES2194841T3
ES2194841T3 ES92925307T ES92925307T ES2194841T3 ES 2194841 T3 ES2194841 T3 ES 2194841T3 ES 92925307 T ES92925307 T ES 92925307T ES 92925307 T ES92925307 T ES 92925307T ES 2194841 T3 ES2194841 T3 ES 2194841T3
Authority
ES
Spain
Prior art keywords
vaccine
gram
negative bacterial
pct
mineral carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92925307T
Other languages
English (en)
Inventor
Donald A Dearwester
David S Roberts
Leroy A Swearingin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2194841T3 publication Critical patent/ES2194841T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PROPORCIONA EN ESTE INVENTO UN NUEVO METODO DE PREPARAR VACUNAS CONTRA BACTERIAS GRAM - NEGATIVAS. EL METODO COMPRENDE PROPORCIONAR UN CONCENTRADO DE PREPARACION ANTIGENICA BACTERIANA GRAM - NEGATIVA, ABSORBER LA PREPARACION CON UN PORTADOR MINERAL CAPAZ DE ENLAZAR LA ENDOTOXINA LIBRE EN LA PREPARACION ANTIGENICA EN UNA CANTIDAD EFECTIVA PARA PRODUCIR UN ENLACE OPTIMO DE ENDOTOXINA Y ANTIGENO Y DILUIR LA PREPARACION ABSORBENTE PARA EMPLEARLA EN UNA VACUNA. TAMBIEN SE PROPORCIONA EN ESTE INVENTO UNA VACUNA PRODUCIDA POR EL METODO DEL INVENTO. TAMBIEN SE PROPORCIONA POR ESTE INVENTO UNA VACUNA BACTERIANA GRAM - NEGATIVA EN DONDE LA MEJORA COMPRENDE UNA CONCENTRACION DE UN PORTADOR MINERAL EN LA VACUNA QUE ES MENOR QUE 5.0 % V/V. TAMBIEN SE PROPORCIONA EN ESTE INVENTO UNA VACUNA BACTERIANA GRAM - NEGATIVA QUE COMPRENDE UN PORTADOR MINERAL EN DONDE LA CANTIDAD DEL PORTADOR MINERAL EN LA VACUNA SE PREDETERMINA POR EL METODO DEL INVENTO. TAMBIEN SE PROPORCIONA EN ESTE INVENTO UN METODO DE VACUNAR UN ANIMAL CONTRA LAS INFECCIONES BACTERIANAS GRAM NEGATIVAS QUE COMPRENDE ADMINISTRAR AL ANIMAL UNA CANTIDAD EFECTIVA DE UNA VACUNA DE ESTE INVENTO.
ES92925307T 1991-11-15 1992-11-13 Procedimiento de produccion de vacunas bacterianas gram negativas. Expired - Lifetime ES2194841T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79248891A 1991-11-15 1991-11-15

Publications (1)

Publication Number Publication Date
ES2194841T3 true ES2194841T3 (es) 2003-12-01

Family

ID=25157051

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92925307T Expired - Lifetime ES2194841T3 (es) 1991-11-15 1992-11-13 Procedimiento de produccion de vacunas bacterianas gram negativas.

Country Status (10)

Country Link
US (1) US5616328A (es)
EP (1) EP0669971B1 (es)
JP (1) JP3043809B2 (es)
AT (1) ATE234916T1 (es)
AU (1) AU667858B2 (es)
CA (1) CA2123222C (es)
DE (1) DE69232969T2 (es)
DK (1) DK0669971T3 (es)
ES (1) ES2194841T3 (es)
WO (1) WO1993010216A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188424A1 (en) * 1994-04-28 1995-11-09 Akihiro Suehara Method of separating protective components of bordetella pertussis
US5885823A (en) * 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
US6749831B1 (en) 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US6713071B1 (en) * 1998-10-22 2004-03-30 Pfizer Inc. Proteins from actinobacillus pleuropneumoniae
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
ZA997138B (en) * 1999-01-29 2001-05-16 Pfizer Prod Inc Erysipelothrix rhusiopathiae antigens and vaccine compositions.
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US6765372B2 (en) 2001-12-14 2004-07-20 Intersil Americas Inc. Programmable current-sensing circuit providing continuous temperature compensation for DC-DC Converter
AU2003289398A1 (en) * 2002-12-18 2004-07-09 Techno Network Shikoku Co., Ltd. Vaccine for fish cold-water disease
US7521059B2 (en) * 2004-06-14 2009-04-21 Fenwick Bradley W Kennel cough vaccine
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
WO2013095973A1 (en) 2011-12-19 2013-06-27 The Rockefeller University Hdc-sign binding peptides
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
WO2022114921A1 (ko) * 2020-11-30 2022-06-02 주식회사 엘지화학 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법
CN113670914B (zh) * 2021-08-19 2024-03-08 青岛易邦生物工程有限公司 一种油乳剂灭活疫苗的细菌内毒素检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750925A (en) * 1980-09-12 1982-03-25 Takeda Chem Ind Ltd Preparation of pertussis toxoid
US4465665A (en) * 1982-03-04 1984-08-14 Smithkline-Rit Detoxified E. coli neurotoxin, preparation thereof and immunological preparations containing it
US4705686A (en) * 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
US4789544A (en) * 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US5101019A (en) * 1987-05-22 1992-03-31 Takeda Chemical Industries, Ltd. Method for removing pertussis endotoxin, a pertussis toxoid and its production
DE69131525T2 (de) * 1990-06-13 1999-11-25 Pfizer Inc., New York Pasteurella multocida toxoid enthaltende impfstoffe

Also Published As

Publication number Publication date
JP3043809B2 (ja) 2000-05-22
EP0669971B1 (en) 2003-03-19
CA2123222A1 (en) 1993-05-27
ATE234916T1 (de) 2003-04-15
JPH07501333A (ja) 1995-02-09
DK0669971T3 (da) 2003-04-22
DE69232969T2 (de) 2004-08-05
US5616328A (en) 1997-04-01
AU3141393A (en) 1993-06-15
AU667858B2 (en) 1996-04-18
EP0669971A1 (en) 1995-09-06
CA2123222C (en) 2001-02-27
EP0669971A4 (en) 1995-04-19
WO1993010216A1 (en) 1993-05-27
DE69232969D1 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
ES2194841T3 (es) Procedimiento de produccion de vacunas bacterianas gram negativas.
IL138798A0 (en) Vaccines and antibodies against bacterial pneumococcal infection
CA2022420A1 (en) Escherichia coli vaccine
AU1915995A (en) Active immunization using a siderophore receptor protein
CY1107571T1 (el) Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
NO1997010I1 (no) Bordetella pertussis P69 antigen
BR9713312B1 (pt) preparado de vacina para uso veterinário útil para produzir imunidade ativa contra uma doença bacteriana ou protozoária.
DE69527986D1 (de) Antigene arznei zur behandlung oder vorbeugung
Yang et al. Specific humoral immune response induced by propionibacterium acnes can prevent Actinobacillus pleuropneumoniae infection in mice
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
ATE356633T1 (de) Vakzin für einen nicht typisierbaren haemophilus influenzae stamm
DE69333402D1 (en) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1
GR3036369T3 (en) Vaccines based on streptokinase.
IL122829A0 (en) Isolated strains of staphylococcus aureus and vaccines manufactured therefrom
AU4778297A (en) Use of an immunoglobulin preparation for producing an oral medicament preventing hemolytic uremic syndrome and preparation for the same
JP3270473B2 (ja) パスツレラ・マルトサイダ・トキソイドワクチン
NO931655D0 (no) Syntetiske lipid a glykokonjugatantigener for anvendelse i vaksiner
AU9168591A (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
SU1405300A1 (ru) Штамм бактерий chlamydia psittaci, используемый для изготовления инактивированной вакцины против хламидиоза свиней